Back to top

AstraZeneca’s Opemalirsen Renal Study Completion: What Investors Should Watch Next

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. AstraZeneca (AZN) has completed a Phase 1 study titled “A Single-Dose, Non...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

AstraZeneca PLC (AZN)